The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Conditional survival of patients with metastatic testicular germ-cell tumors (MT-GCT) treated with first-line curative therapy.
 
Jenny J. Ko
No Relationships to Disclose
 
Brandon David Bernard
No Relationships to Disclose
 
Ben Tran
No Relationships to Disclose
 
Haocheng Li
No Relationships to Disclose
 
Tehmina Asif
No Relationships to Disclose
 
Igor Stukalin
No Relationships to Disclose
 
Margaret Lee
No Relationships to Disclose
 
Daphne Day
No Relationships to Disclose
 
Nimira S. Alimohamed
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Philippe L. Bedard
Consulting or Advisory Role - Genentech/Roche (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Oncothyreon (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer